elapsed_time: 18s
was_input_captured: True
original_text: |
    Patients with a known germline or somatic BRCA pathogenic mutation should have a prior PARP inhibitor and subsequent progression, unless they have a documented history of intolerance or inability to swallow oral medications
inclusion: True
